Metabolic Profile of the Control and Experimental Group Patients after Matching for Age, Gender, and Severity of Disease at Two Monthly Intervals (mg/dL, Mean ± SD)
Triglyceride Control group Experimental group
Total cholesterol Control group Experimental group HDL-C Control group Experimental group
LDL-C Control group Experimental grp VLDL-C Control Group Experimental group
Non-HDL-C Control group Experimental group TC:HDL-C Control group Experimental group
LDL-C:HDL-C Control group Experimental group ApoA1 Control group Experimental group
Control group Experimental group
ApoA1:B Control group Experimental group
26.4 ± 17.0* 28.5 ± 17.8 23.3 ± 10.0** 23.1 ± 8.5***
132.2 ± 28.0* 133.7 ± 45.4 132.0 ± 34.4 145.1 ± 42.3:
108.8 ± 79.6*** 106.5 ± 79.7 81.3 ± 24.0*** 88.7 ± 43.7***
*p < .05, **p < .01, ***p < .001 vs. baseline.
Spirulina effectively lowered the lipids and lipoprotein fraction in these patients, a significant reduction in the atherogenic indices, that is, TC:HDL-C an LDL-C:HDL-C were also observed. Such changes in the lipid levels have also been associated with a lower incidence of CHD.6
The reduction in the elevated lipid levels led to an improvement in the apo A1:B ratio (p < .001) after 4 months of supplementation in the experimental group (Table 4.11). Spirulina supplementation also showed significant reduction in the apo B levels (p < .001) (Table 4.11) in the experimental group after 4 months of Spirulina supplementation. Thus, this beneficial effect of Spirulina suggests that it helped in decreasing the risk of developing cardiovascular disease in these patients and was also helpful in retarding the further progression of renal disease.
In addition, the supplementation of Spirulina in the experimental group also showed substantial reduction in the number of relapses. On the basis of this the clinician had brought down the level of drug to 54% of the initial requirements where as in the control group, the patients required 87% of the initial level for the treatment of nephrotic syndrome. These observations clearly demonstrate and substantiate that Spirulina had shown a remarkable improvement in the prognosis of nephrotic syndrome patients.
Hence, it can be said that Spirulina aided in improving the quality of the experimental group patients in a better way as compared to the patients in the control group.
Was this article helpful?